Drugs / RESEQUINIL
RESEQUINIL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00359944 | Feb 2006 → Sep 2008 | Alzheimer disease | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2009-04-17 | Sumitomo Pharma America, Inc. | Results Discontinuation of development of AC-3933, a therapeutic agent for dementia sumitomo-pharma.com ↗
This time, the Company obtained its Phase II clinical study results in the United States, but the compound did not meet the criteria that the Company has envisaged. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2009-04-17 | Sumitomo Pharma America, Inc. | Discontinuation of development of AC-3933, a therapeutic agent for dementia sumitomo-pharma.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RESEQUINIL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107801 ↗ |
| Known as | AC-3933 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00359944 ↗ |
| Known as | AVE-3933 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107801 ↗ |
| Known as | Radequinil | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107801 ↗ |
| Known as | Radequinilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107801 ↗ |
| Known as | SX-3933 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107801 ↗ |
| Modality | Small molecule | — CHEMBL2107801 ↗ |